Avalyn Pharma said its inhaled perfenidone, APO1, completed enrollment in a large global Phase 2b study over the summer, with 52-week data expected in the second half of next year. Its base case is another Phase 3 study before approval. Inhaled nintetanib, APO2, has a 12-week proof-of-concept study with data expected late in 2027.
AVLN · Avalyn Pharma Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 95%
- Last earnings
- Jun 3, 2026
- Latest filing
- 10-Q · Nov 12
- Price history
- Apr 2026 to Nov 2026
The closing range uses available history since Apr 30, 2026; less than a full year is stored.
Latest documents
Avalyn Pharma reported a nine-month net loss of $85.5 million and $386.6 million in cash, cash equivalents and marketable securities as of September 30, 2026, which it expects to fund operations into 2029.
Avalyn Pharma Inc. started a Phase 1 study of AP03 in healthy volunteers. It had $386.6 million in cash, cash equivalents and marketable securities on September 30, 2026, with runway projected into 2029; third-quarter net loss was $29.7 million.
Avalon said around $400 million of cash extends its runway into 2029, assuming Phase 3 funding for AP01 and AP02. The inhaled profenidone MIST study enrolled 398 patients with progressive pulmonary fibrosis.
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash, cash equivalents, and marketable securities | $413.5M | Second Quarter 2026 | — |
| Net proceeds from initial public offering | $316.6M | Second Quarter 2026 | — |
| Patients randomized in MIST Phase 2b trial | 398 | Second Quarter 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AVLN
this stock
Avalyn Pharma Inc.
|
$1.28B | — | — | — | 5.2% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$132.01B | +14.8% | +46.2% | 33.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.52B | +19.6% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$80.65B | +575.9% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.36B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 18, 2026
- This year
- 18
Avalyn Pharma said its inhaled perfenidone, APO1, completed enrollment in a large global Phase 2b study over the summer, with 52-week data expected in the second half of next year. Its base case is another Phase 3 study before approval. Inhaled nintetanib, APO2, has a 12-week proof-of-concept study with data expected late in 2027.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AVLN | -6.2% | +5.3% | +7.7% | +12.0% | — |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | -0.7% | +11.6% | +13.3% | +17.3% | — |